

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N	A2	(11) International Publication Number: WO 97/14026 (43) International Publication Date: 17 April 1997 (17.04.97)
(21) International Application Number: PCT/CA96/00676 (22) International Filing Date: 10 October 1996 (10.10.96) (30) Priority Data: 60/005,590 12 October 1995 (12.10.95) US 60/007,616 28 November 1995 (28.11.95) US (71)(72) Applicant and Inventor: LANSDORP, Peter [CA/CA]; 312 East 45th Avenue, Vancouver, British Columbia V5W 1X3 (CA). (74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHOD FOR DETECTING MULTIPLE COPIES OF A REPEAT SEQUENCE IN A NUCLEIC ACID MOLECULE		
(57) Abstract A method for detecting or quantitating multiple copies of a repeat sequence in a nucleic acid molecule involving treating the nucleic acid molecule with a probe which is a nucleic acid analogue which is capable of hybridizing to the repeat sequence in the nucleic acid molecule and which is labelled with a detectable substance. The nucleic acid molecule is treated with the probe under conditions permitting the probe to hybridize to the repeat sequences in the nucleic acid molecule. Probe hybridized to complementary repeat sequences is identified in the nucleic acid molecule by directly or indirectly detecting the detectable substance. The method is preferably used for quantitating multiple copies of a repeat sequence in a nucleic acid molecule, preferably a telomere or centromere repeat sequence. Novel probes for use in the method of the invention and kits are described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Title: METHOD FOR DETECTING MULTIPLE COPIES OF A REPEAT SEQUENCE IN A NUCLEIC ACID MOLECULE

FIELD OF THE INVENTION

The present invention relates to methods for detecting and optionally
5 quantitating multiple copies of a repeat sequence in a nucleic acid molecule, preferably a telomere or centromere repeat sequence. The invention also relates to a method for determining the replicative potential of a cell.

BACKGROUND OF THE INVENTION

A large fraction of the DNA of all eukaryotes is made up of repeat sequences
10 ranging from a few copies up to millions. Repeat functional sequences occur at the telomeres and centromeres of eukaryotic chromosomes. Telomeres and centromeres are important structural and functional elements of eukaryotic chromosomes. Telomeres are specialized nucleoprotein structures which are at the end of eukaryotic chromosomes (Blackburn, E.H., Nature (London), 350:569-572, 1991). Telomeres in all vertebrates terminate in tandem arrays
15 of the repeat sequence TTAGGG (Moyzis, R.K., et al., Proc. Natl. Acad. Sci. USA 85:6622-6626, 1988). The repeat sequences are synthesized by the ribonucleoprotein enzyme telomerase, which is composed of both RNA and protein (Greider, C.W., & Blackburn, E.H. Cell 43:405-413, 1985; Morin, G.B. Cell 59:521-529, 1989). In the absence of telomerase, telomeres shorten with cell divisions.

20 Telomeres have been shown to be critical for chromosome stability and function (Blackburn, E.H., Nature (London), 350:569-572, 1991). Telomere loss has been shown to signal cell cycle arrest and chromosomal instability in yeast (Sandell, L.I., & Zakian, V.A., Cell 57:633-643, 1989; and Greider, C.W., & Blackburn, E.H. Cell 43:405-413, 1985). Telomeres in cells have been found to shorten with the age of the cell donor (Allsopp, R.C. et al., Proc. Natl. Acad. Sci. USA 89, 10114-10118, 1992; Lindsey, J. et al., Mutat. Res. 256:45-48,
25 1991; Vaziri, H., et al., Am. J. Hum. Genet. 52:661-667, 1993; Vaziri, H., et al., Proc. Natl. Acad. Sci. USA 91:9857-9861, 1994; and Hastie, N.D., et al., Nature (London), 346:866-868, 1990), Harley C.B. et al., Nature (London) 345:458-460, 1990; Harley, C.B., Mutat. Res. 256:271-282, 1991), and this phenomenon has been implicated by some in aging (Harley, C.B., Mutat.
30 Res. 256:271-282, 1991), and in programmed cell death (Wright et al., Trends Genet 8:193-197, 1992). Abnormalities in telomeres have also been found in malignant cells (Meltzer et al., Nature Genetics 4:252-255, 1993).

The centromere region of mammalian chromosomes consists of tandem arrays of repetitive sequences which consist of various copy numbers of α satellite (Willard, H.F.,
35 Trends Genet. 3:192-198, 1987), β satellite (Waye, J.S., & Willard H.F., Proc. Natl. Acad. Sci. USA 86:6250-6254, 1989) and the three classic satellites I, II and III (Prosser J. et al., J. Mol. Biol. 187:145-155, 1989).

Fluorescent *in situ* hybridization (FISH) techniques have been used to obtain information about the presence of telomeric and centromeric repeat sequences in chromosome preparations. Meyne and Moyzis (in *Methods in Molecular Biology*, Vol. 33: *In Situ Hybridization Protocols*, ed. K.H.A. Choo, 1994, Humana Press Inc., Totowa, NJ, USA) used FISH with synthetic oligonucleotide probes to confirm the presence of repeat telomere and centromere sequences. Directly labeled oligonucleotides should be attractive probes for FISH because of their small size (good penetration properties), single strand nature (no renaturation of probe required), and reproducible, controlled synthesis. However, these probes are not widely used for FISH because of their limited hybridization efficiency. The hybridization efficiency of oligonucleotide probes is modest because of their small size, and because conditions required for hybridization of the probe typically also favour the renaturation of denatured target DNA sequences with the longer homologous complimentary strands, resulting in direct and unfavourable competition for the oligo probe. Oligomer probes also have limited use as probes for single copy sequences.

Significantly, the studies using FISH have not provided optimal visualization of telomeres in a chromosome preparation nor have they provided information about the length of telomere or centromere regions. Southern analysis of the terminal restriction fragment (TRF) length distribution has so far been the only tool for studying telomere length (Allshire RC et al., *Nucl. Acid Res.* 17:4611-4627 and Harley CB et al., *Nature* 345:458-60). However, Southern analysis has a number of technical limitations. The TRF's contain DNA other than the telomeric repeat sequences such as degenerate or non-TTAGGG as well as TTAGGG repeats in blocks other than at the distal end (Allshire et al., *Nucl. Acid Res.* 17:4611-4627; Counter et al., *EMBO J.* 11:1921-9, 1992 and Levy et al., *J. Mol. Biol.* 225:951-960, 1992). There is also interchromosomal variation in both non-TTAGGG and TTAGGG DNA in the TRF and variation in prior replicative histories *in vitro* or *in vivo* of cells in the population of cells required for TRF analysis, which makes it difficult to assess the relationship between cell senescence and TRF length in specific chromosome's and in specific cell types. This is a particular problem in cancer where a variable or unknown number of normal cells may be present in a tumor sample.

It is apparent from the above discussion that there is a need for reliable methods for *in situ* visualization and quantification of telomere and centromere regions in chromosome preparations.

SUMMARY OF THE INVENTION

The present inventor has developed a method for detecting repeat sequences in the genome of a single cell or in an individual chromosome. This has been illustrated by the detection of telomeric repeat sequences at the end of human chromosomes. It was significantly found that the illustrated method results in the highly sensitive and efficient staining of all telomeres in a chromosome preparation. The present inventor also found a

high correlation between fluorescence intensity of telomere sister chromatids in metaphase chromosomes. The method thus allows for the highly sensitive and efficient detection of telomeres in a chromosome preparation, and/or it allows for the quantification of the length of telomeric arrays at individual ends. The method also permits one skilled in the art to
5 determine the effect of telomere loss on cell viability and chromosome behaviour in a variety of disease states.

The method of the invention can also be used to detect and/or quantitate the length of other repeat sequences for example, centromere repeats and polymorphisms of the telomere and centromere repeats.

10 The method of the invention addresses many of the technical limitations of conventional *in situ* hybridization procedures. The limitations of using oligonucleotide probes in *in situ* hybridization has been overcome by using nucleic acid analogue probes, and conditions that allow hybridization of the probes but prevent the renaturation of target DNA. The method of the invention provides a more efficient and sensitive procedure than
15 existing or conventional *in situ* hybridization methods using DNA or RNA oligo probes.

Therefore, broadly stated the present invention relates to a method for detecting multiple copies of a repeat sequence in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe which is a nucleic acid analogue which is capable of hybridizing to the repeat sequence in the nucleic acid molecule and which is
20 labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecule; and, (b) identifying probe hybridized to complementary repeat sequences in the nucleic acid molecule by directly or indirectly detecting the detectable substance.

In an embodiment of the invention, the detectable substance is a fluorophore,
25 an image is formed of the probe hybridized to repeat sequences in the nucleic acid molecule, and, the multiple copies of the repeat sequences in the nucleic acid molecule are detected in the image.

The method of the invention may be used to quantitate the length of multiple copies of a repeat sequence in a nucleic acid molecule based on the direct relationship between
30 the intensity of the signal produced directly or indirectly by the detectable substance, and the length of the multiple copies of the telomere sequence. Therefore, in accordance with a specific embodiment, the invention provides a method for quantitating the length of multiple copies of a repeat sequence in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe which is a nucleic acid analogue which is capable of hybridizing to
35 the repeat sequence in the nucleic acid molecule and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecule; (b) identifying probe hybridized to repeat sequences in the nucleic acid molecule by detecting a signal produced directly or indirectly by the detectable substance;

and, (c) optionally, quantitating the length of the multiple copies of the repeat sequences in the nucleic acid molecule based on the direct relationship between the intensity of the signal produced directly or indirectly by the detectable substance and the length of the multiple copies of the repeat sequence.

- 5 The repeat sequence which is detected and/or quantitated is preferably a telomere or centromere repeat sequence, most preferably a human telomeric repeat sequence. In a preferred embodiment, multiple copies of the telomere repeat sequence TTAGGG in a nucleic acid molecule are detected using a probe containing the sequence CCCTAA.

- 10 In a particularly preferred embodiment of the invention, a method is provided for quantitating the length of multiple copies of the telomere repeat sequence TTAGGG in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe in the presence of a blocking reagent and a denaturing agent, preferably formamide, most preferably 70% formamide, and permitting the probe to hybridize to TTAGGG telomere repeat sequences in the nucleic acid molecule, wherein the probe is a nucleic acid analogue
15 comprising the sequence CCCTAA and the probe is labelled with a fluorophore, and, (b) forming an image of probe hybridized to TTAGGG telomere repeat sequences in the nucleic acid molecule; and, (c) quantitating the length of the TTAGGG telomere repeat sequences in the nucleic acid molecule based on the direct relationship between fluorescence intensity and the length of the multiple copies of the telomere sequence.

- 20 The present invention also relates to a method for determining the replicative potential of a cell by quantitating the length of multiple copies of a telomere repeat sequence TTAGGG in nucleic acid molecules in the cell comprising (a) treating the nucleic acid molecules with a probe, under conditions permitting the probe to hybridize to telomere repeat sequences in the nucleic acid molecules, wherein the probe is a nucleic acid
25 analogue comprising the sequence CCCTAA and the probe is labelled with a detectable substance; (b) identifying probe hybridized to TTAGGG repeat sequences in the nucleic acid molecules by detecting signals produced directly or indirectly by the detectable substance; (c) quantitating the length of the multiple copies of the TTAGGG telomere repeat sequence based on the direct relationship between the intensity of the signals produced directly or indirectly
30 by the detectable substance and the length of the multiple copies of the telomere repeat sequence and (d) determining the replicative potential by comparing the quantitated length of the multiple copies of the telomere repeat sequence with the length of multiple copies of the telomere repeat sequence associated with cells having a known replicative potential.

- The invention still further contemplates a method for distinguishing normal
35 cells from abnormal cells (e.g. tumor cells) in a cell suspension comprising: (a) treating the cells in the cell suspension with a probe which is a nucleic acid analogue which is capable of hybridizing to a repeat sequence in nucleic acid molecules in the nuclei of the cells and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to

repeat sequences in the nucleic acid molecules; (b) identifying probe hybridized to repeat sequences in the nucleic acid molecules by detecting a signal produced directly or indirectly by the detectable substance; and, (c) determining whether the cells are normal cells or abnormal cells by comparing the signal with a signal associated with known normal cells or abnormal cells. Preferably, the repeat sequence which is quantitated is a telomere repeat sequence, and the probe comprises the sequence CCCTAA.

In preferred embodiments of the methods of the invention, the detectable substance is a fluorophore, a digital image is created and the length of the multiple copies of the repeat sequence in the nucleic acid molecule is quantitated from the specific fluorescence intensity calculated from photon counts at defined positions within the digital image.

The methods of the invention may also be used to determine the effect of a substance on telomerase activity. Accordingly, the invention provides a method for determining the effect of a substance on telomerase activity comprising (a) treating cells having telomerase activity with a probe which is a nucleic acid analogue comprising the sequence CCCTAA and which is labelled with a detectable substance, preferably a fluorophore, and with a substance suspected of affecting telomerase activity, under conditions permitting the probe to hybridize to TTAGGG telomere repeat sequences in nucleic acid molecules in the cells; (b) identifying probe hybridized to TTAGGG telomere repeat sequences in the nucleic acid molecule by directly or indirectly detecting the detectable substance; (c) quantitating the length of multiple copies of the TTAGGG telomere repeat sequence in the nucleic acid molecules based on the direct relationship between the intensity of the signal produced directly or indirectly by the detectable substance and the length of the multiple copies of the telomere repeat sequence, and (d) determining the effect of the substance by comparing the quantitated length of the multiple copies of the telomere repeat sequence with the length of multiple copies of the telomere repeat sequence quantitated for the preparation in the absence of the substance.

The method of the present invention may be adapted to detect and/or quantitate multiple copies of repeat sequences in nucleic acid molecules in individual cells in suspension. In particular, the invention provides a method for quantitating multiple copies of repeat sequences in nucleic acid molecules in cells in suspension comprising; (a) treating the cells with a probe which is a nucleic acid analogue which is capable of hybridizing to the repeat sequences in the nucleic acid molecules and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecules; (b) subjecting the treated cells to flow cytometry or image cytometry to detect the detectable substance and produce a signal corresponding to the amount of probe hybridized to repeat sequences in the nucleic acid molecules; and (c) optionally, quantitating the length of the multiple copies of the repeat sequences in the nucleic acid molecules based on the relationship between the intensity of the signal and the length of the multiple copies

of the repeat sequences. In an embodiment, the method is used to quantitate multiple copies of a telomere repeat sequence TTAGGG. Preferably, the detectable substance is detected using flow cytometry which has the advantage that thousands of nuclei can be measured per second, and multiple other cell parameters (such as DNA content) can be analyzed simultaneously. The method is particularly suited for analyzing normal and abnormal cells, including lymphocytes, from blood and bone marrow.

The invention also contemplates a method for distinguishing normal cells from abnormal cells (e.g. tumor cells) in a suspension containing normal cells and abnormal cells comprising: (a) treating the cells in the cell suspension with a probe which is a nucleic acid analogue which is capable of hybridizing to a repeat sequence in nucleic acid molecules in the nuclei of the cells and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecules; (b) subjecting the treated cells to flow cytometry or image cytometry to detect the detectable substance and produce a signal corresponding to the amount of probe hybridized to repeat sequences in the nucleic acid molecules; and (c) determining whether the cells are normal cells or abnormal cells by comparing the signal with a signal obtained for known normal cells or abnormal cells.

The invention also contemplates novel Peptide Nucleic Acid (PNA) probes. In particular, the invention relates to a Peptide Nucleic Acid (PNA) probe comprising the following sequence: TTAGGG, CCCTAA, CCCCAA, CCCCAAAA, CCCACA, CCCTAAA, CCCCT, or CCATT. Preferred Peptide Nucleic Acid (PNA) probes of the invention include CCCTAA CCCTAA, CCCTAACCCTAACCCTAA, TTAGGGTTAGGG, TTAGGGTTAGGGTTAGGG, CCATTCCATTCCATT, CCCATAACTAAACA, GAGAATTGAACCACCG, TTCCTGCCGTTCG, (GGC)₅, or (TCG)₅.

The invention also contemplates kits for performing the methods of the invention.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, reference is made herein to various publications, which are hereby incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described with reference to the accompanying drawings, in which:

Figure 1 shows images of *in situ* hybridization of telomeric nucleic analogue probes to metaphase chromosomes and interphase nuclei from cultured human fetal liver cells;

Figure 2 shows examples of digital images of *in situ* hybridization of FITC-(C₃TA₂)₃ PNA probe to metaphase chromosomes used for calculations of fluorescence intensity of individual telomeres;

Figure 3 are graphs showing correlation of telomere fluorescence of sister
5 chromosomes in metaphase chromosomes;

Figure 4 are graphs showing the distribution of telomere fluorescence intensity on metaphase chromosomes from different tissues;

Figure 5 shows flow histograms of calibration beads (top) and the indicated cell types (bottom) after suspension PNA hybridization with telomere probe (solid lines) and
10 a control probe (c-Myc, dashed lines); and

Figure 6 are histograms and a graph showing that fluorescence spot intensity after hybridization with fluorescently labeled telomere PNA probe correlates with the length of T₂AG₃ inserts in plasmids.

DETAILED DESCRIPTION OF THE INVENTION

15 As hereinbefore mentioned, the present invention relates to a method for detecting and/or quantitating the length of multiple copies of a repeat sequence in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe which is a nucleic acid analogue which is capable of hybridizing to repeat sequences in the nucleic acid molecule, and which is labelled with a detectable substance, under conditions permitting the
20 probe to hybridize to the repeat sequences in the nucleic acid molecule; (b) identifying probe hybridized to the repeat sequences in the nucleic acid molecule by detecting a signal produced directly or indirectly by the detectable substance; and (c) optionally quantitating the length of multiple copies of a repeat sequence in the nucleic acid molecule based on the direct relationship between the intensity of the signal produced directly or indirectly by the
25 detectable substance and the length of the multiple copies of the repeat sequence.

The nucleic acid molecules that are analyzed using the methods of the invention are preferably double stranded DNA molecules. However, the methods of the invention may be adapted to quantitate single stranded DNA, and RNA molecules.

The nucleic acid molecules which are detected and/or quantitated using the
30 methods of the invention contain repeat sequences which may be multiple copies of a single sequence, or regularly alternating combinations of several sequences. The repeat sequences may be "pure" with no other kinds of sequences inserted, or clusters interrupted at points by one or more repeats of a pseudogene, or other moderately repeated element. Examples of repeat sequences that may be analyzed using the methods of the invention are telomere
35 repeat sequences (e.g. GGGATT, GGGATT, GGGGA, GGGTGT, GGGGTTTT, GGGGTT), centromere repeat sequences (e.g. AATGGAATGGAATGG, TGTTTAGTTATGGG, CGGTGGTTCAATTCTC), or the gene encoding 5S RNA (AAGGGACGGCAAGC). Trinucleotide simple tandem repeats may also be analyzed using the methods of the

invention. For example, the trinucleotide simple tandem repeat CCG which gives rise to one group of fragile sites on human chromosomes which are responsible for the most common familial form of mental retardation; and the trinucleotide simple tandem repeat AGC which gives rise to a number of neurological disorders (Sutherland, G.R. and R.I. Richards, Proc. Natl. Acad. Sci. USA 92:3636, 1995) may be analyzed using the methods of the invention.

Nucleic acid molecules present in morphologically preserved chromosomes, cells and tissue sections may be analyzed using the methods of the invention. The nucleic acid molecules are typically from metaphase cells. Biological materials are morphologically preserved by fixation using conventional methods (See for example, A.G. Everson Pearce, Histochemistry Theoretical and Applied, 4th Ed., Churchill Livingstone, Edinburgh, 1980 for details relating to the general techniques of preparing tissue sections and fixation). They may be fixed on a support such as slides or filters using a fixative. By way of example, samples of hematopoietic cells may be fixed by spinning small volumes of cells onto slides. The preparations containing the nucleic acid molecules may also be pretreated on the support. Pretreatments include RNase treatment to remove endogenous RNA, protease treatment (e.g. pepsin) to increase the accessibility by digesting protein surrounding the target nucleic acid molecules, and detergent treatment when it is suspected that lipid membrane components have not been extracted by other procedures.

In a preferred embodiment of the invention for detecting multiple copies of a telomeric repeat sequence in a nucleic acid molecule and optionally quantitating the length of the multiple copies of the telomeric repeat sequence, cells are cultured, treated with colcemid (e.g. 0.1µg/ml), harvested about 2 to 18 hours later, and after washing hypotonic swelling cells are fixed and stored in methanol/acetic acid. Cells are fixed to slides by spinning small volumes (e.g. 10-100µl) of cells in acetic acid, drying the cells overnight, and immersing in a buffer (e.g. PBS), prior to fixation in formaldehyde (e.g. 4%). The cells are then washed, treated with pepsin (e.g. 1 mg/ml) and rinsed with buffer. The formaldehyde fixation procedure is repeated and the slides are dehydrated in ethanol and dried.

In the methods of the invention employing image or flow cytometry, the nucleic acid molecules are present in cell suspensions. The cells are typically interphase cells. Generally, in the cytometry methods, cells are harvested, washed, and fixed with an agent such as PFX (Caltag Fixation and Permeabilization reagent) or PermeaFixt (Ortho #775999). The cells in the suspension may be pretreated with RNase and pepsin as described herein.

The preparations containing the nucleic acid molecules are treated with a probe. The probe is a nucleic acid analogue and it is capable of hybridizing to a repeat sequence. Nucleic acid analogues differ from natural DNA in that they do not have a deoxyribose or ribose backbone. Suitable probes for use in the present invention are those constructed from the nucleic acid analogue known as Peptide Nucleic Acid (PNA) which contains a polyamide backbone (See PCT WO 92/2070, which is incorporated herein in its

entirety by reference), or analogues having cyclic backbone moieties comprising furan or morpholine rings, or acyclic backbone moieties as described in PCT WO 86/05518, which is incorporated herein in its entirety by reference. Preferably, the probe used in the methods of the invention is a PNA. Determination of whether a probe hybridizes to a repeat sequence
5 can be accomplished by hybridizing the probe to a nucleic acid molecule containing multiple copies of the repeat sequence using the hybridization media and conditions described herein.

In an embodiment of the invention for detecting and optionally quantitating the length of telomere repeats in a nucleic acid molecule, the hybridization probe is a PNA containing the repeat sequence TTAGGG, CCCTAA, CCCCAA, CCCCAAAA, CCCACA,
10 CCCTAAA, or CCCCT, most preferably CCCTAA. For example, a probe which may be used in the present invention is a PNA having the following sequence: CCCTAACCTAA, CCCTAACCTAACCTAA, TTAGGGTTAGGG, or TTAGGGTTAGGGTTAGGG.

In another embodiment of the invention for detecting and optionally quantitating the length of multiple copies of a centromere repeat sequence common to human
15 satellites II and III in a nucleic acid molecule the hybridization probe is a PNA containing the repeat sequence CCATT, for example, CCATTCCATTCCATT. In other embodiments of the invention for detecting and optionally quantitating the length of multiple copies of a centromere repeat sequence specific for the centromeric region of the X chromosome, and for detecting and optionally quantitating the length of multiple copies of a centromere repeat
20 sequence for specific chromosome 18 in a nucleic acid molecule, the hybridization probe is preferably a PNA having the sequence CCCATAACTAAACA, and GAGAATTGAACCAACCG respectively.

The method of the invention may also be used to detect and optionally quantitate the length of the 5S RNA gene, and the probe which is used in the method is
25 preferably a PNA having the sequence TTCCCTGCCGTTCCG. Further, the invention may be used to detect and/or quantitate the trinucleotide simple tandem repeat CCG and the trinucleotide simple tandem repeat AGC, using PNA probes for example having the following sequences: (GGC)₅, and (TCG)₅.

The probe used in the method of the invention is preferably labelled with
30 one or more detectable substances. In the direct methods contemplated by the present invention the probe is labelled with a detectable substance so that the formed hybrids can be visualized microscopically after the *in situ* hybridization procedure, or detected using flow cytometry or image cytometry. Detectable substances which may be used in direct methods include fluorophores, isotopes, and chemiluminescent compounds. Examples of suitable
35 isotopes include iodine I¹²⁵, I¹³¹ or tritium; examples of suitable fluorophores include fluorescein-isothiocyanate (FITC), tetramethyl rhodamine isothiocyanate (TRITC), amino-methyl coumarin acetic acid (AMCA) (Molecular Probes, Eugene, OR.), Texas Red (Molecular Probes, Eugene, OR.) and carboxymethylindocyno dyes such as Cy2, Cy3, or Cy5 (Biological

- 10 -

Detection Systems, Pittsburgh, PA), and, an example of a chemiluminescent material is luminol. The probe may be labelled with these detectable substances using methods conventionally known in the art.

In the indirect methods contemplated by the present invention the probe is
5 labelled with a detectable substance so that the formed hybrids are visualized after reacting with an element (e.g. a substrate, antibody, etc.) which results in a detectable signal. Detectable substances which may be used in indirect methods include enzymes and haptens. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; and examples of suitable haptens include biotin and
10 digoxigenin. By way of example, when biotin is used as the detectable substance, *in situ* hybridized sequences are identified using (strept)avidin or anti-biotin antibodies. The probe may be labelled with enzymes and haptens using methods conventionally known in the art (see for example, Patterson et al., Science 260:976-979, 1993).

It will be appreciated that a probe used in a method of the invention may be
15 labelled with more than one detectable substance. For example, one probe may be labelled with two or more fluorophores. It will be appreciated that the probe may be labelled with detectable substances for both direct and indirect methods. For example, a probe may be labelled with both a fluorophore and an enzyme or hapten. The method of the invention may also use differently labelled probes. For example, the method may use three probes having
20 the same nucleic acid sequence but each labelled with a different detectable substance, for example, three different fluorophores.

The detectable substance(s) may provide a colorimetric, photometric, radiometric etc. signal which can be detected by a wide variety of means. For example, the method of the invention could employ a suitable detection device capable of detecting a
25 change in absorption density, a change in fluorescent, or radioactive emission, or a shift in the absorbance of a characteristic λ max.

In a preferred embodiment of the invention the probe is labelled with a fluorophore such as fluorescein-isothiocyanate (FITC), tetramethyl rhodamine isothiocyanate (TRITC), amino-methyl coumarin acetic acid (AMCA) (Molecular Probes,
30 Eugene, OR.), Texas Red (Molecular Probes, Eugene, OR.), or carboxymethylindocyanine dyes such as Cy2, Cy3, or Cy5 (Biological Detection Systems, Pittsburgh, PA), and images of fluorophore labelled probes hybridized to target repeat sequences in the nucleic acid molecule are created using conventional techniques known in the art (See for example, Nederlof PM et al., Cytometry 13:839-845, 1992 which is incorporated herein in its entirety
35 by reference). Preferably, the images are formed electronically, most preferably digital images are formed.

Generally, the instrumentation needed to create a digital image consists of a microscope system, a detector for collection of images, and computer hardware and software

for image storage and analysis. For fluorescence microscopy objective lenses are generally used with high magnification and high numerical aperture, since these characteristics determine the spatial resolution and light collecting properties. By way of example, a Leits Dialux epifluorescence microscope equipped with a 100 W mercury-arc lamp and a Neofluor 5 1,40 NA oil objective may be used to measure fluorescence, and the filter used for the selection of the fluorophore may be as follows: PL450-SP490 (excitation filter), DM510 (dichroic mirror), and LP515-SP560 (emission filters).

A detector for imaging the FISH results should be selected so that it has sufficient sensitivity to detect the fluorescing signals obtained by FISH. Ideally the detector 10 also provides a linear response to a wide range of wavelengths, has a high signal to noise ratio, and has wide dynamic range and little geometric aberrations. The cooled CCD camera generally fulfils these requirements (Aikens RS et al., *Methods Cell Biol.* 29:291, 1989, Hiraoka et al., *Science* 238:36-41, 1987, Photometrics, Tucson, Arizona), with a Kodak chip with 1,024 x 1,345 elements of 6.8 x 6.8 μm each.

15 The image collection and image analysis may be performed as described in Smith, L.C. et al, (*Methods Enzymol.* 129:857-873, 1986). The intensity of a spot may be calculated as the integrated intensity of all pixels within the area of the spot corrected for the (local) background. The local background may be determined by the minimum-maximum digital filtering technique (Verbeek P.W. et al., *Signal Processing* 15:249-258, 1988).

20 In embodiments of the invention where a digital image is formed, the length of the multiple copies of the repeat sequence in the nucleic acid molecule is quantitated from the specific fluorescence intensity calculated from photon counts at defined positions within the digital image as described in detail in Example 1.

Methods of the invention are contemplated herein which employ flow 25 cytometry or image cytometry. In such methods, the cells pass through detectors, and the signals generated by the detectable substance are resolved and detected using instruments such as confocal microscopes or optical sectioning fluorescence microscopes. A flow histogram is obtained which shows signals corresponding to the intensity of the detectable substance. The relative length of multiple copies of a repeat sequence are determined based on the 30 intensity of the signal. Suitable detectors and instruments which may be used to carry out flow cytometry and image cytometry are commercially available, for example, the FACScan (Becton Dickinson, San Jose, CA) flow cytometer, and the DeltaVision optical sectioning fluorescence microscope from Applied Precision (Mercer Island, WA).

35 The concentration of probe used in the methods described herein may be selected by titrating increasing amounts of the probe and determining the concentrations which provide plateau hybridization. These concentrations are preferably used in the method of the invention. In a preferred embodiment of the invention for visualizing and optionally determining the length of telomere repeats in nucleic acid molecules in

morphologically preserved materials, the amount of hybridization probe used is between 0.1-10 µg/ml, preferably 0.3 µg/ml.

The hybridization probe is incorporated into a hybridization medium. The hybridization medium and hybridization conditions are selected so as to favour
5 hybridization of the probe with the denatured nucleic acid molecules in the preparation to be tested, and disfavour renaturation of the denatured nucleic acid molecules with their complementary single strand.

Generally, a hybridization medium is selected which has a low ionic strength and typically contains a buffer, denaturing agent and blocking reagent. Suitable
10 buffers include TRIS and Hepes. Examples of suitable denaturing agents are formamide and DMSO. A blocking reagent is selected so that it substantially blocks non-specific binding of the probe. Examples of blocking reagents which may be used in the method of the invention are protein solutions such as BMP (Boehringer-Mannheim, GmbH, FRG).

In a preferred embodiment of the method of the invention for detecting
15 and/or determining the length of multiple copies of a telomeric repeat in a nucleic acid molecule, the hybridization medium contains a buffer (e.g. 10 mM TRIS, pH=7.2), formamide 50% -100%, most preferably 70% formamide, BMP (1-5% W/V, most preferably 1% W/V), and the labelled probe.

The hybridization medium containing the hybridization probe may be
20 applied to the morphologically preserved biological materials. Generally, 5 to 20 µl, preferably 10 µl of the hybridization medium is applied per cell preparation. The hybridization probe is applied and the target nucleic acid molecules are denatured simultaneously by heat or pH treatment, preferably the mixture is treated for 1 to 24 hours at 70 to 80°C, most preferably 3 minutes at 80°C. Hybridization is carried out for about 0.1 to
25 24 hours, most preferably 2 hours, at 4 to 40°C, preferably 25°C. After hybridization, the slides are washed with a buffer (e.g. Tween and/or Tris buffer).

In the methods of the invention for detecting and/or quantitating multiple copies of a repeat sequence in cell suspensions, about 10 to 1000 µl, preferably 200 µl of hybridization medium is added to the cells. The hybridization is carried out for about 5 min
30 to 24 hours, preferably 8 to 18 hours at room temperature. After hybridization the cells are washed with buffer (e.g. formamide/BSA/Tween; Tris/NaCl/Tween/BSA) and resuspended in buffer (e.g. PBS and 7AAD for FACSort; DAPI for FACStar).

The method of the present invention in providing a means to detect and/or quantitate the length of repeat sequences in nucleic acid molecules has many practical
35 applications. The efficient and sensitive hybridization in the method of the invention permits the detection of repetitive sequences in many cytogenic analyses. In particular, the method provides more reliable detection of chromosomal abnormalities than conventional methods. Furthermore, since nearly 25% of the human genome consists of repetitive

sequences, data on the distribution of these sequences, and in particular quantitative data, will permit highly specific aneuploidy enumeration and detection, as well as enumeration and detection of telomere abnormalities.

The quantification of the length of telomeric arrays at individual ends of
5 chromosomes using the methods of the invention permits one skilled in the art to determine the effect of telomere length on cell viability and chromosome behaviour. In particular, the methods of the invention may be used to analyze pathophysiology of telomere length dynamics in cells from normal and abnormal tissues.

The methods described herein may be used to obtain quantitative information
10 on the relationship between telomere length and disease which will guide the development of novel therapeutic strategies involving for example transplantation and genetic manipulation of primitive hematopoietic cells for the treatment of a variety of disorders.

The methods of the invention may also be used to assess the replicative
potential of a cell. The term "replicative potential" refers to the ability of a cell to divide,
15 or the number of times a cell can turnover. Replicative potential may be directly linked to the length of telomeres, and the latter provide an indication of the age of a cell. Therefore, the present invention also provides a method for determining the replicative potential of a cell which involves quantitating telomere length using the method described above and illustrated in the examples. In particular, the method comprises (a) treating nucleic acid
20 molecules in cells with a probe which is a nucleic acid analogue comprising the telomere repeat sequence CCCTAA, which is labelled with a detectable substance, under conditions such that the nucleic acid molecules are denatured and the probe hybridizes to telomere repeat sequences in the nucleic acid molecules; (b) identifying probe hybridized to TTAGGG
telomere repeat sequences in the nucleic acid molecule by detecting signals produced directly
25 or indirectly by the detectable substance; (c) quantitating the length of the multiple copies of the telomere repeat sequence based on the direct relationship between the intensity of the signal produced directly or indirectly by the detectable substance and the length of the multiple copies of the telomere sequence; and (d) determining the replicative potential by
comparing the quantitated length of the multiple copies of the telomere repeat sequence with
30 the length of multiple copies of the telomere repeat sequence associated with cells having a known replicative potential (e.g. normal cells, disease cells). The preparation of a sample containing nucleic acid molecules, and the hybridization, denaturation and imaging steps may be carried out as described herein.

The method for determining the replicative potential of a cell can be used to
35 monitor the progression of disease. The advanced stages of some diseases (e.g. some cancers) are characterized by aberrant cells with short telomeres and an indefinite replicative potential. Generally, primary and metastatic human tumors have extremely short telomeres, express the enzyme telomerase, and thus express a high replicative potential.

The average length of the TTAGGG repeat arrays has been estimated to be about 1 to 2 kb per chromosome end. Therefore, the quantification of telomeres in tumor cells from a patient may suggest that the tumor is a primary or metastatic tumor, and guide development of drugs capable of inhibiting telomerase activity.

5 The determination of replicative potential may be particularly useful in monitoring the progression of leukemia. In the initial stages of leukemia, altered signal transduction pathways and/or altered probabilities of differentiation events in a single cell will result in numerical expansion of the leukemic cells. This expansion is eventually limited by critical shortening of telomeric DNA, resulting in signals that trigger cell cycle arrest but
10 also chromosomal instability. Further progression of the disease may involve selection of cells that ignore or can bypass the cell cycle arrest signal and eventually selection of cells that express the enzyme telomerase.

 In some diseases the replicative potential of aberrant cells or infected cells declines with the progression of the disease. For example, the replicative potential of
15 lymphocytes declines over time after infection with the Human Immunodeficiency Virus (HIV). Therefore, the progression of an HIV infection may be monitored by determining the replicative potential i.e. telomere length in nucleic acid molecules from specific lymphocyte subpopulations from a patient infected with HIV.

 It may also be possible to extend or maintain the proliferative potential of
20 cells for example, adult stem cells by forced expression of exogenous or endogenous telomerase activity. The method of the present invention may be used to monitor telomere length and determine telomerase activity which provides optimal proliferation of the cells.

 The methods of the invention may be used for the diagnostic analysis of tissue sections to distinguish cells with different proliferative histories. For example, tumor
25 cells that by morphology alone are often difficult to distinguish from neighboring normal cells can be distinguished from normal cells by a weaker "telomere-staining" in their nucleus following the methods of the invention. Because telomere shortening in tumor cells is a parameter that is independent from commonly used morphological parameters, quantitative information on telomere fluorescence per nucleus is an extremely valuable aid in the diagnosis
30 or analysis of tissue sections of patient material.

 The present invention provides a method of measuring telomere repeat content in individual cells by flow cytometry. Currently no methods exist to assess the replicative history (and implicated replicative potential) of cells by flow cytometry. However, such a method would permit identification of abnormal cells in a variety of
35 disorders. Cells that, by morphology alone appear normal, could, for the first time, be identified as being abnormal in telomere content, and therefore cell divisional history, relative to other cells from the same individual. This type of analysis is particularly useful in the analysis of blood cells. For example, the presence of morphologically "normal"

lymphocytes could raise the suspicion of a pathologist if such cells by telomere-PNA-FISH flow cytometry analysis stained significantly weaker than other cells from the same patient. Such cells could be sorted and analyzed for the presence of tumor-specific genetic abnormalities of, for example, lymphoma cells. Measurements of telomere repeat content in different subpopulations of lymphocytes could provide useful information about the immune status of an individual. For example, the functional properties of lymphocytes with a low telomere repeat content, as measured using the method of the invention using flow cytometry, may be compromised. Identification of such cells may therefore be of prognostic significance in that the presence of such cells may predict the onset of specific immune defects. An example of such a use of such a method is the identification of specific lymphocyte subpopulations (i.e. cells expressing CD4 or CD8) in patients infected with the HIV virus that are at a high risk for developing AIDS. Similar assessment of telomere content in antigen-specific subpopulations may provide information on the immune status of individuals that cannot be obtained otherwise.

The methods described herein may also be used to determine the effect of a substance on telomerase activity. Accordingly, the invention provides a method for determining the effect of a substance on telomerase activity comprising (a) treating cells having telomerase activity with a probe which is a nucleic acid analogue comprising a telomere repeat sequence containing the sequence CCCTAA and which is labelled with a detectable substance, and with a substance suspected of affecting telomerase activity, under conditions such that the probe hybridizes to TTAGGG telomere repeat sequences in nucleic acid molecules in the cells; (b) identifying probe hybridized to complementary telomere repeat sequences in the nucleic acid molecules by detecting a signal produced directly or indirectly by the detectable substance; (c) quantitating the length of the multiple copies of the telomere repeat sequence based on the direct relationship between the intensity of the signal produced by the detectable substance and the length of the multiple copies of the telomere sequence and (d) determining the effect of the substance by comparing the quantitated length of the multiple copies of the telomere repeat sequence with the length of multiple copies of the telomere repeat sequence quantitated for the preparation in the absence of the substance.

Cells having telomerase activity which may be used in the above-described method include cells in adult male germline tissues such as testes, cells from malignant or metastatic tumors such as breast, ovarian, prostate, CNS, head and neck, colon, uterine cancer, and hematopoietic cells from late stage chronic lymphocytic leukemia (CLL).

Substances identified using the present invention may be used as inhibitors or stimulators of telomerase activity. Inhibitors of telomerase identified using the method described herein may be useful as anti-cancer therapeutics. Substances which stimulate

telomerase activity may be useful in the treatment of conditions where the replicative potential of cells declines over time such as after infection with HIV.

The reagents suitable for applying the methods of the invention to detect multiple copies of repeat sequences, preferably, telomere repeat sequences, may be packaged into convenient kits providing the necessary materials packaged into suitable containers. For example, such kits may include the necessary probes, reagents, and buffers, and instructions for *in situ* hybridization by means of the methods described herein. The kits may also include suitable supports useful in performing the methods of the invention.

The following non-limiting examples are illustrative of the present invention:

EXAMPLES

Example 1

The following materials and methods were used in the studies set out in the example:

15 Hybridization Protocol:

Cultures of hematopoietic cells from human fetal liver, umbilical cord blood and adult bone marrow were prepared as described in Hastie, N.D. et al., Nature 346:866, 1990. At various time intervals colcemid (0.1 µg/ml) was added to the cultures and cells were harvested 2 to 18 hours later. After washing and hypotonic swelling, cells were fixed and stored in methanol/acetic acid fixative using standard procedures. Cells were fixed to slides by spinning small volumes (10-100 µl) of cells in 2 ml of 50% acetic acid. The slides were dried overnight in air and immersed in Phosphate Buffered Saline (PBS) for 5 min. prior to fixation in 4% formaldehyde in PBS for 2 minutes, washed in PBS (3 x 5 min.) and treated with pepsin (P-7000, Sigma, St. Louis, MO) at 1 mg/ml for 10 min. at 37°C at pH 2.0. After a brief rinse in PBS, the formaldehyde fixation and washes were repeated and the slides were dehydrated in ethanol and air dried. Ten microliters of hybridization mixture containing 70% formamide, 0.3 µg/ml FITC-(C₃TA₂)₃ PNA probe (PBIO/Biosearch Product, Bedford, MA), 1% (W/V) blocking reagent (Boehringer-Mannheim, GmbH, FRG) in 10mM Tris pH 7.2 was added to the slide, a coverslip (20x20mm) was added and DNA was denatured by heat for 3 min. at 80°C. After hybridization for 2 hours at room temperature, the slides were washed with 70% formamide in 10 mM Tris pH 7.2 (2x15 min.) and with 0.05 M tris 0.15 M NaCl pH 7.5 containing 0.05% Tween-20 (3x5 min.). The slides were then dehydrated with ethanol, air dried and covered by 5-10 µl of antifade solution (VectaShield, Vector Laboratories Inc., Burlingame, CA) containing 0.1 µg/ml of propidium iodide.

35 Image Collection and Analysis:

Digital images were recorded with a KAF 1400 slow scan CCD camera (Photometrics; Tuscon, AZ) on an Aristoplan fluorescence microscope (Leica, Wetzlar, Germany), interfaced to a Sun 330 Workstation. Microscope control and image analysis was

performed under "SCIL Image" (TN), Delft; Netherlands). A PL Fluotar 100x NA 1.3 objective lens and filter blocks I3 and N2.1 were used for the visualization of FITC and Propidium, respectively. A short pass SP 560 nm filter was inserted at the emission side when the green FITC emission was recorded, to minimize crosstalk of red propidium signal into this channel. The camera housing contained a short pass SP 630 nm filter to block the far red and infra red light during all measurements. Integration times were chosen such that approximately 50% of the dynamic range of the camera was used (typically 9 sec for the FITC telomere signal and 6 sec for the Propidium counter stain). Digital images of 12 bit were corrected for pixel shifts (occurring due to the change of optical filters) by software procedures as described in Nederlof, P.M. et al., Cytometry 13:846, 1992. A second correction procedure was performed to subtract the dark current image and to correct for uneven illumination of the microscopic field and local differences in sensitivity of the camera, using constantly fluorescing uranyl glass as a reference object. Thus recorded and corrected images were segmented on the basis of grey value thresholding to find the contours of the chromosomes and the telomeric regions. For each of the telomeric regions, a background subtraction was performed based on min/max filtering. Each chromosome was divided in four regions by a watershed algorithm, and the integrated fluorescence intensity of each telomeric region was calculated and divided by the integration time used for normalization purposes. Finally, for each chromosome the spot intensities were ordered two by two and summarized.

20 RESULTS

In initial studies, FITC-labeled DNA, RNA and PNA (C_3TA_2)₃ oligonucleotide probes were directly compared for the detection of T₂AG₃ repeats on human metaphase chromosomes by *in situ* hybridization. At selected hybridization conditions (Meyne, J., and Moyzis, R.K., Methods Mol. Biol. 33:63, 1994) all three probes showed fluorescence of some telomeres. Hybridization with the RNA probe appeared somewhat more efficient than with the DNA oligo but neither of these two probes allowed staining of all telomeres in agreement with previous findings by others (Moyzis, R.K. et al, Proc. Natl. Acad. Sci. U.S.A 85: 6622, 1988, Meyne, J. and Moyzis, R.K., Methods Mol. Biol. 33:63, 1994). The PNA probe showed a high background fluorescence but also intense staining of most telomeres. Further optimization of the hybridization protocol for use with the PNA probe (see above) resulted in microscopic images exemplified in Figures 1 and 2.

In particular, Figure 1 shows *in situ* hybridization of peptide nucleic acid probe to metaphase chromosomes and interphase nuclei from cultured human fetal liver cells. Hybridization of the FITC-labeled (C_3TA_2)₃ PNA probe at room temperature for 2 hours was performed at low ionic strength 10 mM Tris/70% formamide in the presence of excess protein as described herein. Chromosomes were counterstained with propidium iodide (orange, A&B) or diamidinophenylindole (DAPI, Blue, C). Photographs were taken directly from the microscope using a 100X objective. Note that in Figure 1 essentially all metaphase

chromosomes show four fluorescent spots and that the fluorescence intensity of sister chromatid telomere pairs appears to be linked. Specific fluorescence was completely inhibited by including a 3-fold molar excess of an unlabeled $(T_2AG_3)_2$ peptide nucleic acid oligonucleotide but not a 100-fold molar excess or random nucleotide peptide oligomer in the
5 hybridization mixture.

Figure 2 shows an example of the digital images of *in situ* hybridization of FITC- $(C_3TA_2)_3$ PNA probe to human fetal liver metaphase chromosomes used for calculations of fluorescence intensity of individual telomeres. Microscopic images were captured with a cooled CCD camera (Photometrics) using blue excitation and filters for separate collection of
10 green fluorescence (FITC) and green plus red fluorescence (mainly Propidium iodide). The image of total fluorescence (B) was used to identify chromosomes and areas in (A) for calculations of specific hybridization signals on individual telomeres (see description of image collection and analysis above).

Essentially all metaphase chromosomes showed four fluorescent spots at
15 telomeric positions (Figure 1A and 1C) and up to 92 spots were observed in interphase nuclei (Figure 1B). This was an unexpected result, given the limitations in the efficiency of regular oligonucleotide hybridization (Moyzis, R.K. et al, Proc. Natl. Acad. Sci. U.S.A 85: 6622, 1988, Meyne, J. and Moyzis, R.K., Methods Mol. Biol. 33:63. 1994) or the more sensitive primed *in situ* hybridization (A.J. Therkelsen, et al., Cell Genet. 68:115, 1995) for detection of
20 telomeric repeats. Furthermore, the telomere fluorescence of sister chromatids appeared to be of similar intensity (Figure 1A and 1C), an impression that was confirmed by image analysis (Figure 2 and 3). For quantification purposes digital images from metaphase chromosomes after hybridization with the PNA probe and counter staining with propidium iodide (PI) were captured using a CCD camera (see description of image collection and
25 analysis above). An example of this analysis is shown in Figure 2 and Table 1.

In particular, Table 1 shows the heterogeneity in telomere fluorescence signals from individual chromosomes of a single metaphase. CCD camera images of telomere fluorescence *in situ* hybridization (FISH) on a metaphase spread of a cultured fetal liver cell (shown in Figure 2 and used for image analysis as described above for Figure 2). The
30 fluorescence intensity of individual telomeres (expressed in arbitrary units) is shown for the 26 chromosomes (arbitrary numbers) indicated in Figure 2. Note the heterogeneity in fluorescence per telomere (i.e. compare data for chromosome 11, spot 1-2 = highest average telomere fluorescence, with chromosome 20, spot 3-4 = lowest average telomere fluorescence; ratio 11.1-2/20.3-4 = 5.9) and in the total telomere fluorescence per chromosome (i.e.
35 fluorescence per chromosome (i.e. total fluorescence chr 11/chr 9 = 2.8).

Table 1 and Figure 2 illustrate that within the individual metaphase considerable heterogeneity in fluorescence per telomere and in total telomere fluorescence per chromosome are observed.

When telomere fluorescence values of all the chromosomes analyzed in this study ($n=1273$) were analyzed, a good correlation between the values derived from sister chromatid telomere pairs was observed. In particular, Figure 3 shows graphs correlating telomere fluorescence of sister chromosomes in metaphase chromosomes. The fluorescence intensity of individual telomere spots on all chromosomes analyzed in this study ($n=1273$, from hematopoietic cell cultures of fetal liver, cord blood, bone marrow and chronic myeloid leukemia cells) were ranked in two sister chromatid pairs corresponding to their location on the chromosome (pair 1: spot 1-spot 2; pair 2: Spot 3-spot 4). The fluorescence intensity of all spots was comparable (mean \pm s.d., spot 1: 564 ± 273 ; spot 3: 567 ± 288 ; spot 4: 563 ± 279) but was significantly better correlated between sister chromatid pairs than between telomeres on opposite ends of the chromosome (correlation coefficients: spot 1-spot 2=0.71; spot 1-spot 3=0.35; spot 2-spot 3=0.34; spot 3-spot 4=0.72; spot 1-spot 4= 0.33; spot 2-spot 4= 0.33; spot 1 +2 - spot 3 +4 =0.39).

Striking differences in fluorescence intensity of telomeres in cells from fetal liver, adult bone marrow and chronic myeloid leukemia cells were observed. Figure 4 are graphs showing the distribution of telomere fluorescence intensity on metaphase chromosomes from different tissues. Telomere fluorescence (in arbitrary units) was calculated from digital images as described above for Figure 2 and in the description of image analysis above. Values for telomere fluorescence (4/chromosome) within the indicated range are shown for 3 different individual metaphases (numbers corresponding to those in Table 2) as well as the pool of all chromosomes analyzed from each slide/tissue. Note that the distribution of telomere fluorescence within an individual metaphase corresponds well to the overall distribution within the pool of metaphase chromosomes of each tissue and that this distribution is not symmetrical particularly so in chromosomes of normal adult bone marrow and chronic myeloid leukemia cells.

Table 2 shows heterogeneity in telomere length on chromosomes from different hematopoietic tissues. Metaphase preparations from the indicated tissues were hybridized with the PNA-telomere probe and the fluorescence intensity of individual telomeres as well as whole chromosomes (sum of four telomere spots) were measured from digital images described above for Figure 2. The results shown are from individual slides that contained metaphases with at least 10 chromosomes that could be analyzed (i.e. non-overlapping, correct segmentation, four spots). The same fixed bone marrow cells were used to prepare two different slides. Min-max values for telomere fluorescence were obtained by averaging the sum of two sister chromatid telomere values.

Several points are worth noting from this data. First independent of the tissue analyzed, telomere fluorescence values varied to a greater extent between chromosomes than was anticipated from the data of flow sorted chromosomes reported by Moyzis (R.K. Moyzis, et al., Proc. Natl. Acad. Sci. U.S.A. 85:6622, 1988). Within individual metaphases,

the total telomere signal was found to vary up to 3-fold per chromosome and up to 6-fold per telomere. The minimum telomere fluorescence values (expressed on a linear scale and presumably linearly related to the number of T_2AG_3 repeats) were found to differ less than 2-fold between the various tissues (Table 2). The latter suggests that a threshold or minimum number of T_2AG_3 repeats is required for telomere function. This notion is compatible with studies of telomeres in yeast (E.H. Blackburn, Cell 77:621, 1994 and L.L. Sandell, and V.A. Zakian, Cell 75:729, 1993) and the observation that immortal tumour cells express high levels of functional telomerase (N.W. Kim, et al., Science 266:2011, 1994). Secondly, the variation between fluorescence intensity values from different metaphases on the same slide and between slides (BM-1 versus BM-2) appears relatively small (Table 2 and Figure 4). Together with the observed linkage of sister chromatid telomere fluorescence (Figure 3), this observation underscores the notion that the PNA-FISH protocol described herein approaches 100% efficiency for the detection of T_2AG_3 repeats. Finally, the distribution of telomere fluorescence appears to be non-random, particularly so in metaphases derived from normal bone marrow and chronic myeloid leukemia cells (Figure 4). In normal adult bone marrow cells this non-random distribution may be the result of *in vivo* selection of cells that avoided postulated critical telomere shortening (C.B. Harley et al., Exp. Gerontol. 27:375, 1992 and 20) or, alternatively, a selective action of telomerase on chromosomes with short telomeres. This latter hypothesis is compatible with the recent observation that telomerase activity in yeast is negatively regulated by telomere length and internal telomeric repeat sequences (D.R. Howard et al., J. Immunol. 136:4013, 1986) as well as the presence of measurable telomerase activity in normal bone marrow cells. Based on the observations shown in Figure 4 and Table 2 and these considerations, it appears that telomerase activity in normal hematopoietic cells is restricted to chromosomes with short telomeres resulting in continuous replication-dependent shortening of long telomeres and the maintenance of short telomeres. Careful analysis of telomere fluorescence from individual chromosomes in clonally propagated normal cells from different tissues using the PNA-FISH technology described here could be used to test this hypothesis. This approach makes it possible to determine whether differences in telomere length are randomly distributed among chromosomes in cells from different tissues.

Example 2

Protocol for Flow FISH

The method of the invention to detect and/or quantitate telomere repeats may be adapted to detect and/or quantitate telomere repeats in nucleic acids in individual cells in suspension. A proposed protocol is as follows. Cells are harvested and washed in phosphate buffered saline (PBS) by centrifuging in a microfuge (30 seconds at 5000g), and resuspended in a known volume of PBS. The cells are counted using Trypan Blue, and the viability of the cells is recorded (total cell number live + dead). The cells are distributed

over Eppendorf tubes up to 4×10^7 per tube, PBS is added, and the mixture is centrifuged in a microfuge. The pellet is resuspended in PFX™-A (Caltag Fixation & Permeabilization reagent) (max - 10^7 cells/200 μ l PFX), mixed, and incubated for 15 minutes at room temperature. PBS is added, and the mixture is centrifuged in a microfuge. The pellet is resuspended in the PFX-B (same volume and cell numbers as for PFX-A), incubated for 10 min RT, PBS is added, and the mixture is centrifuged in a microfuge. The pellet is resuspended in 200 μ l PBS per 10^7 cells and mixed well. RNaseA (from 500 μ g/ml stock in glycerol - Sigma) is added to a final concentration of 10 μ g/ml — 1:50, mixed and incubated for 30 min in 37°C (water bath) with occasional shaking. PBS is added and the tubes are centrifuged in a microfuge. The pellet is resuspended in 200 μ l/ 10^7 cells acidified water, pH=2 + pepsin [frozen (-20°C) stock in PBS @ 50 mg/ml - Sigma] at a final concentration 0.5 mg/ml — 1:100. Pepsin is thawed just before making a working solution, and it is added to the cells. After adding pepsin, the tubes are put on ice, and then transferred to a 37°C waterbath. The tubes are incubated 10 min, put on ice, 1 ml of PBS is added, and they are centrifuged in a microfuge. The pellet is resuspended in 200 μ l (per 10^7 cells) of PFX-A, max - 2×10^7 cells/400 μ l, mixed well, and incubated for 15 minutes at room temperature. PBS is added to the top and the tubes are centrifuged in a microfuge. The pellet is resuspended in 200 μ l (per 10^7 cells) of PFX-B, max - 2×10^7 cells/400 μ l, mixed well and incubated for 5 minutes at room temperature. PBS is added, and the tubes are centrifuged in a microfuge. One more wash is carried out with PBS, and the pellet is resuspended in PBS, and divided over Eppendorf tubes for the required number of samples (e.g. no-probe, c-myc, tel, etc.). PBS is added, and the tubes are centrifuged in a microfuge. The supernatant is almost completely removed with a needle suction leaving max ~ 10- 20 μ l over the pellet. The hybridization mixture is added and the mixture is mixed well with the Eppendorf tip. The maximum cell number per 100 μ l mixture is about 2×10^6 and the maximum volume in a tube should not exceed 500 μ l. The minimal volume of hybridization mixture added per sample is about 200 μ l. The tubes are left in RT for 10 min, and placed in a Thermomixer set up to 87°C (the actual temperature inside a tube is ~80°C) for 10 min shaking. The tubes are incubated in RT overnight (~17 hrs) protected from light. The tubes are centrifuged (Beckman centrifuge at maximum RPMI for 7 min) and the supernatant is removed. The pellets are vortexed well before adding washing solution, and they are vortexed again after adding the washing solution. It is recommended that the samples stay in RT for ~ 10 min between all the washes. Two washings are carried out with 1 ml 70% formamide/0.1% BSA/ 0.1% Tween 20 and centrifuging in a Beckman centrifuge at maximum RPMI for 7 min. Three washings are then carried out with 1 ml TNTB (Tris/NaCl/0.1% Tween20/0.1%BSA) and centrifuging in a Beckman centrifuge. The first TNTB wash is at maximum RPMI for 7 min, the second is at 1800 PRPMI for 6 min, and the third washing is at 1500 RPMI for 5 min. The pellet is resuspended in PBS+ 7AAD

@0.25µg/ml final (FACSort) or DAPI@ 0.05 µg/ml final (FACStar+). About 20 µl of cells is left in each tube for counting. The cell recovery is recorded. The samples are analyzed with a linear amplification for all FACS parameters. The instrument setting and mean channel fluorescence is recorded for all the samples.

5 **Example 3**

Preliminary data indicate that quantitative telomere measurements in interphase cells are possible (Figure 5). Figure 5 shows flow histograms of calibration beads (top) and the indicated cell types (bottom) after suspension PNA hybridization with telomere probe (solid lines) and a control probe (c-Myc, dashed lines). These preliminary results were obtained with Permeafix™ fixed cells, after RNase and pepsin treatment and hybridization with FITC-labeled (C₃TA₂)₃ PNA. Note that nuclei of mouse spleen cells (MSPL) have a 3-fold increased fluorescence relative to human adult peripheral blood (APB) cells and that human fetal liver (FL) cells show a brighter telomere signal than adult blood and chronic myeloid leukemia (CML) cells.

15 In the preliminary studies variables known or expected to be important for suspension *in situ* hybridization were systematically explored. The effect of a number of variables on the specific and non-specific hybridization of PNA probes to different human cell types was examined. For this purpose, FITC-labeled PNA specific for telomeric T₂AG₃ DNA and a single copy gene such as the c-Myc-gene respectively was used. Variables that were investigated include: 1) fixation; 2) permeabilization; 3) proteolytic digestion; 4) denaturation and 5) hybridization. Because all these variables are to a large extent interdependent, the selected protocol and concentrations of reagents represents only an example of a workable protocol. The variables that were tested are listed in Table 3.

25 The protocol development efforts resulted in cells/nuclei with 92 fluorescent spots in interphase (46 chromosomes, 2 telomeres each). Unlike metaphase chromosomes, these fluorescence signals will not be captured efficiently in a single plane. Harvesting fluorescence from multiple focal planes may be achieved using confocal microscopy. This possibility has been examined using suboptimal hybridized nuclei on two different confocal microscopes (one at UBC, Vancouver, Canada, and one at the Fred Hutchinson Cancer Research Center in Seattle). Relative to deconvolution fluorescence microscopy, the studies showed poor resolution and/or detection of telomere-specific fluorescence signals probably due to bleaching of the signals due to the high intensity laser light. Better results in terms of spatial resolution, bleaching and detection sensitivity were obtained using optical sectioning fluorescence microscopes from Applied Precision (Hiraoka Y. et al., Biophys J. 57:325-333, 1990); instrumentation at the Fred Hutchinson Cancer Research Center in Seattle) and the system described by Fay et al. (Carrington WA et al., Science 268:1483-1487, 1995).

35 **Example 4**

Fluorescence intensity correlates with number of T₂AG₃ repeats in plasmids.

- 23 -

Telomere fluorescence intensity values were found to correlate with terminal restriction fragment size (Figure 6) and, more strikingly, with actual size of T₂AG₃ repeats in recent PNA-FISH experiments with purified plasmids (containing T₂AG₃ repeat inserts of 0.2, 0.4, 0.8, and 1.6 kb, respectively; plasmids obtained from Dr. Titia de Lange, Rockefeller University, New York) as is shown in Figure 6. Figure 6 shows fluorescence spot intensity after hybridization with fluorescently labeled telomere PNA probe correlates with the length of T₂AG₃ inserts in plasmids.

From these experiments, it is concluded that the median fluorescence intensity obtained by image analysis from PNA-FISH chromosomes can be used to estimate the length of T₂AG₃ repeats. However, the fluorescence intensity distribution in Figure 6 also shows that not all plasmids of a given size yield an identical fluorescence intensity value. Possible explanations include -biological-variables such as loss of DNA during the hybridization procedure and/or conformational changes of target DNA that are incompatible with PNA hybridization. Such variables can be superimposed on the measurement (instrument/image analysis) related variability that are known from experiments with calibration beads to account for errors up to 30-40%. For these reasons, measurements are repeated for 15-25 metaphases per cell type to yield acceptable histograms (see i.e., Figure 6). The mean fluorescence intensity from such histograms is then used to calculate the mean telomere length on that chromosome arm in the cells used to prepare that slide.

While what is shown and described herein constitutes various preferred embodiments of the subject invention, it will be understood that various changes can be made to such embodiments without departing from the subject invention, the scope of which is defined in the appended claims.

Table 1

chr number	Pair 1		Pair 2		sum
	spot 1	spot 2	spot 3	spot 4	
1	698	340	651	622	2311
2	306	334	642	583	1865
3	347	293	727	548	1915
4	546	957	1154	826	3483
5	393	631	609	675	2308
6	478	464	408	581	1931
7	485	431	562	438	1916
8	1071	717	742	923	3453
9	407	357	633	386	1783
10	617	1015	705	657	2994
11	1648	1355	507	372	3882
12	442	483	400	393	1718
13	928	584	383	567	2462
14	712	568	462	359	2101
15	765	529	432	430	2156
16	782	892	1092	964	3730
17	454	307	615	384	1760
18	760	405	689	685	2539
19	398	373	735	521	2027
20	378	405	262	344	1389
21	756	505	774	683	2718
22	312	496	409	407	1624
23	298	359	527	471	1655
24	555	479	456	410	1900
25	641	700	765	475	2581
26	701	774	1085	501	3061

Table 2

Tissue	Metaphase	# Chromosomes	Chromosome Values					Telomere Values					
			Min	Max	Ratio	Mean	S.D.	Min	Max	Ratio	Mean	S.D.	
FL	1	18	1405	5796	4.12	3101	980	299	1443	4.82	806	264	
	2	23	1228	4116	3.35	2603	605	210	1137	5.41	628	198	
	3	21	1466	4900	3.34	3050	797	360	1770	4.91	764	253	
	4	24	1602	4059	2.53	2861	682	295	1449	4.9	692	226	
	5	14	2019	3738	1.85	2971	492	386	1144	2.96	738	167	
	6	18	1475	4028	2.73	2735	807	191	1234	6.45	682	224	
	7	19	1273	3548	2.78	2224	569	267	978	3.66	542	181	
	8	11	2078	4277	2.05	2842	796	349	1117	3.2	716	250	
	Pool	148	1568	4307	2.84	2798	715	294	1284	4.53	695	220	
BM-1	1	15	974	3233	3.31	1948	726	166	901	5.43	487	202	
	2	14	1015	2463	2.42	1493	431	106	686	6.44	367	141	
	3	12	1311	2808	2.14	1727	432	249	943	3.78	431	146	
	4	20	1081	2716	2.51	1702	543	221	781	3.53	429	154	
	5	18	1083	4019	3.71	2006	708	201	1277	6.36	498	221	
	6	16	1540	3007	1.95	1972	407	237	840	5.53	472	128	
	Pool	95	1167	3041	2.67	1808	541	197	905	4.84	449	165	
	BM-2	1	14	1285	3157	2.45	1958	671	254	992	3.91	467	168
		2	24	1372	3778	2.75	2180	719	209	1074	5.12	522	217
3		11	1328	2690	2.03	2054	418	263	835	3.17	477	138	
4		14	767	2770	3.61	1822	631	139	942	6.78	456	224	
5		17	1175	3098	2.63	1783	468	219	919	4.19	433	142	
6		13	811	2763	3.41	1921	538	177	712	4.2	465	178	
7		10	874	2915	3.33	1605	697	174	867	4.97	401	221	
Pool		103	1087	3024	2.88	1903	591	205	906	4.59	460	184	
CML		1	23	886	2144	2.41	1306	350	161	845	5.25	308	128
	2	12	1041	1953	1.88	1391	319	174	769	4.41	343	142	
	3	20	943	1872	1.98	1163	229	172	412	2.4	283	69	
	4	11	751	1448	1.93	1052	255	157	476	3.03	273	88	
	Pool	66	905	1854	2.05	1227	288	166	625	3.77	301	106	

Table 3. Variables in the development of suspension FISH.

	<u>Fixative</u>	<u>Reference</u>
	Paraformaldehyde	Arkesteijn GJA, et al Cytometry 19: 353-360, 1995, and Brady G,et al.Curr Biol 5: 909-922, 1995.
5	Formaldehyde	Ravichandran KS,et al. J Immunol Methods 153: 249-259, 1992.
	Ethanol	van Dekken H, et al. Cytometry 11: 153-164, 1990.
	Streck Tissue Fixative	Patterson BK, et al. Science 260: 976-979, 1993.
	Permeafix™	Studies herein
10	<u>Permeabilization</u>	
	Triton-X600	Arkesteijn GJA, et al Cytometry 19: 353-360, 1995, Hoy CA et al.. Cytometry 10: 718-725, 1989.
	SDS	Wallner G,et al. Cytometry 14: 136-143, 1993.
	Tween	van Dekken H, et al. Cytometry 11: 153-164, 1990;
15		Ravichandran KS,et al. J Immunol Methods 153:249-259, 1992.
	<u>Proteolytic Digestion</u>	
	Proteinase K	Patterson BK, et al. Science 260: 976-979, 1993
	Trypsin	Arkesteijn GJA,et al. Cytometry 19:353-360, 1995.
20	Pepsin	
	<u>Denaturation</u>	
	Temperature	Arkesteijn GJA,et al. Cytometry 19: 353-360, 1995;Hoy CA et al., Cytometry 10: 718-725, 1989
25	0.1 M HCl	van Dekken H, et al. Cytometry 11: 153-164, 1990.

I CLAIM:

1. A method for detecting multiple copies of a repeat sequence in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe which is a nucleic acid analogue which is capable of hybridizing to repeat sequences in the nucleic acid molecule and
5 which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecule; and, (b) identifying probe hybridized to repeat sequences in the nucleic acid molecule by directly or indirectly detecting the detectable substance.
2. A method as claimed in claim 1, wherein the detectable substance is a fluorophore,
10 isotope, or chemiluminescent compound.
3. A method as claimed in claim 1, wherein the detectable substance is a fluorophore, and in (b) probe hybridized to repeat sequences is determined by forming an image of the probe hybridized to repeat sequences in the nucleic acid molecule, and, detecting the multiple
15 copies of the repeat sequences in the nucleic acid molecule by detecting fluorescence in the image.
4. A method as claimed in claim 1, wherein the detectable substance is an enzyme or hapten.
5. A method for quantitating the length of multiple copies of a repeat sequence in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe which is
20 a nucleic acid analogue which is capable of hybridizing to the repeat sequence in the nucleic acid molecule and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecule; (b) identifying probe hybridized to repeat sequences in the nucleic acid molecule by detecting a signal produced
25 directly or indirectly by the detectable substance; and, (c) quantitating the length of the multiple copies of the repeat sequences in the nucleic acid molecule based on the direct relationship between the intensity of the signal produced directly or indirectly by the detectable substance and the length of the multiple copies of the repeat sequence.
6. A method as claimed in claim 1 or 5 wherein, the repeat sequence is a telomere or
30 centromere repeat sequence, most preferably a human telomeric repeat sequence.

7. A method as claimed in claim 1 or 3 wherein, the repeat sequence is TTAGGG and the probe contains the sequence CCCTAA.
8. A method for quantitating the length of multiple copies of the telomere repeat sequence TTAGGG in a nucleic acid molecule comprising (a) treating the nucleic acid molecule with a probe which is a nucleic acid analogue comprising the sequence CCCTAA which is labelled with a fluorophore, in the presence of a blocking reagent and a denaturing agent, preferably formamide, most preferably 70% formamide, and permitting the probe to hybridize to TTAGGG telomere repeat sequences in the nucleic acid molecule, and, (b) forming an image of probe hybridized to TTAGGG telomere repeat sequences in the nucleic acid molecule; and, (c) quantitating the length of the TTAGGG telomere repeat sequences in the nucleic acid molecule based on the direct relationship between fluorescence intensity and the length of the multiple copies of the telomere sequence.
9. A method for determining the replicative potential of a cell by quantitating the length of multiple copies of a telomere repeat sequence TTAGGG in nucleic acid molecules in the cell comprising (a) treating the nucleic acid molecules with a probe which is a nucleic acid analogue comprising the sequence CCCTAA and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to TTAGGG telomere repeat sequences in the nucleic acid molecules; (b) identifying probe hybridized to TTAGGG telomere repeat sequences in the nucleic acid molecule by detecting a signal produced directly or indirectly by the detectable substance; (c) quantitating the length of the multiple copies of the TTAGGG telomere repeat sequence based on the direct relationship between the intensity of the signal produced directly or indirectly by the detectable substance and the length of the multiple copies of the telomere repeat sequence and (d) determining the replicative potential by comparing the quantitated length of the multiple copies of the telomere repeat sequence with the length of multiple copies of the telomere repeat sequence associated with cells having a known replicative potential.
10. A method for determining the effect of a substance on telomerase activity comprising (a) treating cells having telomerase activity with a probe which is a nucleic acid analogue comprising the sequence CCCTAA and which is labelled with a detectable substance, preferably a fluorophore, and with a substance suspected of affecting telomerase activity, under conditions permitting the probe to hybridize to TTAGGG telomere repeat sequences in nucleic acid molecules in the cells; (b) identifying probe hybridized to TTAGGG telomere repeat sequences in the nucleic acid molecules by detecting a signal produced directly or indirectly by the detectable substance; (c) quantitating the length of multiple copies of the TTAGGG telomere repeat sequence in the nucleic acid molecules based on the direct

relationship between the intensity of the signal produced directly or indirectly by the detectable substance and the length of the multiple copies of the telomere repeat sequence, and (d) determining the effect of the substance by comparing the quantitated length of the multiple copies of the telomere repeat sequence with the length of multiple copies of the telomere repeat sequence quantitated for the preparation in the absence of the substance.

11. A method for quantitating multiple copies of repeat sequences in nucleic acid molecules in cells in suspension comprising; (a) treating the cells with a probe which is a nucleic acid analogue which is capable of hybridizing to the repeat sequence in the nucleic acid molecule and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecule; (b) subjecting the treated cells to flow cytometry or image cytometry to detect the detectable substance and produce a signal corresponding to the amount of probe hybridized to repeat sequences in the nucleic acid molecule; and (c) quantitating the length of the multiple copies of the repeat sequences in the nucleic acid molecule based on the relationship between the intensity of the signal and the length of the multiple copies of the repeat sequence.

12. A method as claimed in claim 11 wherein the repeat sequence is a telomere repeat sequence.

13. A method as claimed in claim 12 wherein the telomere repeat sequence is TTAGGG and the probe contains the sequence CCCTAA.

14. A method as claimed in claim 11, wherein the detectable substance is a fluorophore.

15. A method as claimed in claim 11 wherein the cells are lymphocytes.


16. A method for distinguishing normal cells from a tumor cells in a cell suspension containing normal cells and tumor cells comprising: (a) treating the cells in the cell suspension with a probe which is a nucleic acid analogue which is capable of hybridizing to a repeat sequence in nucleic acid molecules in the nuclei of the cells and which is labelled with a detectable substance, under conditions permitting the probe to hybridize to repeat sequences in the nucleic acid molecule; (b) subjecting the treated cells to flow cytometry or image cytometry to detect the detectable substance and produce a signal corresponding to the amount of probe hybridized to repeat sequences in the nucleic acid molecule; and (c) determining whether the cells are normal cells or tumor cells by comparing the signal with a signal obtained for known normal cells or tumor cells.

- 30 -

17. A Peptide Nucleic Acid (PNA) probe comprising the following sequence: TTAGGG, CCCTAA, CCCCAA, CCCCAAAA, CCCACA, CCCTAAA, CCCCT, or CCATT.
18. A Peptide Nucleic Acid (PNA) probe comprising the following sequence: CCCTAACCCTAA, CCCTAACCCTAACCCTAA, TTAGGGTTAGGG, or
5 TTAGGGTTAGGGTTAGGG.
19. A kit comprising at least one probe which is a nucleic acid analogue which is capable of hybridizing to the repeat sequence in the nucleic acid molecule and which is labelled with a detectable substance, and reagents, buffers and instructions for performing the method as claimed in claim 1.

1/6


FIGURE 1



SUBSTITUTE SHEET (RULE 26)

2/6


FIGURE 2



SUBSTITUTE SHEET (RULE 26)

3/6


FIGURE 3



SUBSTITUTE SHEET (RULE 26)


4/6

FIGURE 4




5/6

FIGURE 5



6/6

FIGURE 6



SUBSTITUTE SHEET (RULE 26)